These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31380815)

  • 1. Exploring the outcome of multiple sclerosis among Saudi adult patients. A single-centered cross-sectional study at King Abdulaziz Medical City in Riyadh, Saudi Arabia.
    Alanazi AM; Al-Rashoud JR; Aljahani JM; Alotaibi AF; Althubaiti AM; Kojan SM; Aljumah MA; Abulaban AA
    Neurosciences (Riyadh); 2019 Jul; 24(3):168-175. PubMed ID: 31380815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of depression and anxiety among adult patients with multiple sclerosis at Riyadh City, Saudi Arabia.
    Alharbi NA; Alawi SH; Alharbi YM; Alharbi MY; Alsamarh TN; Aldubaiyan AA; Alwasil SA; Alomairi AA
    Neurosciences (Riyadh); 2022 Apr; 27(2):71-78. PubMed ID: 35477919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life among multiple sclerosis patients in Saudi Arabia.
    Algahtani HA; Shirah BH; Alzahrani FA; Abobaker HA; Alghanaim NA; Manlangit JS
    Neurosciences (Riyadh); 2017 Oct; 22(4):261-266. PubMed ID: 29057850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring physicians' prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods.
    Al-Omar HA; Alsowaida N; Aldosari L; Mayet A; Bunyan R; Aljumah M
    BMC Neurol; 2023 Mar; 23(1):135. PubMed ID: 37004011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence of Comorbidities Associated with Multiple Sclerosis in Saudi Arabia.
    Alnajashi H; Wali A; Aqeeli A; Magboul A; Alfulayt M; Baasher A; Alzahrani S
    Ann Afr Med; 2024 Oct; 23(4):600-605. PubMed ID: 39138964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.
    AlJumah M; Bunyan R; Al Otaibi H; Al Towaijri G; Karim A; Al Malik Y; Kalakatawi M; Alrajeh S; Al Mejally M; Algahtani H; Almubarak A; Cupler E; Alawi S; Qureshi S; Nahrir S; Almalki A; Alhazzani A; Althubaiti I; Alzahrani N; Mohamednour E; Saeedi J; Ishak S; Almudaiheem H; El-Metwally A; Al-Jedai A
    BMC Neurol; 2020 Feb; 20(1):49. PubMed ID: 32035478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of acute stress with multiple sclerosis onset and relapse in Saudi Arabia.
    AlZahrani AS; Alshamrani FJ; Al-Khamis FA; Al-Sulaiman AA; Al Ghamdi WS; Al Ghamdi OA; Mohammad MY; Alshayea MS; Alhazmi RA; Alkhaja MA
    Saudi Med J; 2019 Apr; 40(4):372-378. PubMed ID: 30957131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between plasma homocysteine level and metabolic syndrome. A record-based study of Saudi patients attending King Abdulaziz Medical City in Riyadh, Saudi Arabia.
    Saeed A; Al Shehri M; Al Saleb A; Othman F; Al Hazmi M; Al Amri F; Ferwana M; Al Yousef MZ; Al Turki M
    Saudi Med J; 2020 Sep; 41(9):947-954. PubMed ID: 32893276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of social stigma among multiple sclerosis patients in Saudi Arabia: A cross-sectional study.
    Algahtani RM; Zahirah MOA; Alsuni ZI; Alfahmi AS; Alfahmi AS; Kabli NA
    Neurosciences (Riyadh); 2024 Oct; 29(4):246-251. PubMed ID: 39379077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of safety and effectiveness of oral multiple sclerosis medication.
    Al Turaiki AM; Al Ammari MA; Alabdulkarim DA; Althemery AU
    Saudi Med J; 2019 Nov; 40(11):1116-1122. PubMed ID: 31707408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.
    Alsaedi EQ; Alsaedi MQ; Mansuri FA
    Cureus; 2022 Jun; 14(6):e25851. PubMed ID: 35832757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.
    Raffel J; Wallace A; Gveric D; Reynolds R; Friede T; Nicholas R
    PLoS Med; 2017 Jul; 14(7):e1002346. PubMed ID: 28692670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA class II polymorphism in Saudi patients with multiple sclerosis.
    Al Jumah M; Kojan S; Al Shehri AM; Al Balwi M; Al Abdulkarim I; Masuadi EM; Alhaidan Y; Alabdulrahman A; Fakhoury HM; Hajeer AH
    HLA; 2018 Jan; 91(1):17-22. PubMed ID: 29131543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Burden of Multiple Sclerosis Patients' Caregivers in Saudi Arabia.
    Algahtani H; Shirah B; Bayazeed A; Alghamdi A; Almailabi M; Algharib M; Alkahtani F
    Cureus; 2020 Jan; 12(1):e6658. PubMed ID: 31966949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.